Method and kit for discriminating between breast cancer and benign breast disease

Patent metadata

Field	Value
Publication number	US-9410188-B2
Application number	US-201013696937-A
Country	US
Kind code	B2
Filing date	May 28, 2010
Priority date	May 28, 2010
Publication date	Aug 9, 2016
Grant date	Aug 9, 2016

Abstract

A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.

First claim

The invention claimed is:

1. A method comprising the following steps:
a) obtaining a biological sample comprising mRNA from a patient and optionally reverse transcribing the mRNA to produce cDNA,
b) contacting the mRNA or the cDNA from the biological sample with at least four reagents, each reagent comprising at least one oligonucleotide respectively specific for each of at least four different target genes, wherein the at least four reagents comprise reagents specific for no more than 28 target genes, the no more than 28 target genes selected from the group consisting of genes respectively comprising the full length nucleic acid sequences set forth in SEQ ID NO: 1 to 44, and the at least four reagents being specific for at least four different target genes that comprise the full length nucleic acid sequences set forth in:
1) SEQ ID NO: 1 and
2) SEQ ID NO: 2 or 3; and
3) SEQ ID NO: 4; and
4) SEQ ID NO: 5 or 6; and

c) measuring an expression level for each of the at least four target genes to obtain an expression profile for the patient.

2. The method as claimed in claim 1 , wherein in step b) the mRNA or cDNA is brought into contact with reagents specific for a combination of 28 target genes, and the expression level of the 28 genes is measured in step c) to obtain the expression profile for the patient.

3. The method as claimed in claim 1 , wherein the biological sample taken from the patient is a blood sample.

4. The method as claimed in claim 1 , wherein each of the specific reagents of step b) comprises at least one hybridization probe.

5. The method as claimed in claim 4 , wherein each of the specific reagents of step b) further comprises at least one primer.

6. The method as claimed in claim 5 , wherein each of the reagents specific for a target gene of step b) comprises one hybridization probe and two primers.

7. A kit comprising at least four reagents, each reagent comprising at least one oligonucleotide respectively specific for each of at least four different target genes, wherein the at least four reagents comprise reagents specific for no more than 28 target genes, the no more than 28 target genes selected from the group consisting of genes respectively comprising the full length nucleic acid sequences set forth in SEQ ID NO: 1 to 44, and the at least four reagents being specific for at least four different target genes that comprise the full length nucleic acid sequences set forth in:
1) SEQ ID NO: 1 and
2) SEQ ID NO: 2 or 3; and
3) SEQ ID NO: 4; and
4) SEQ ID NO: 5 or 6, and
wherein at least one oligonucleotide has a detectable label directly attached thereto or wherein the oligonucleotides are immobilized to a solid substrate.

8. The kit as claimed in claim 7 , comprising reagents specific for a combination of 28 target genes.

9. A method comprising manufacturing the kit of claim 7 .

10. A method comprising manufacturing the kit of claim 8 .

11. The method as claimed in claim 9 , wherein each of the reagents comprises at least one hybridization probe.

12. The method as claimed in claim 11 , wherein each of the reagents further comprises at least one primer.

13. The method as claimed in claim 12 , wherein each of the reagents comprises one hybridization probe and two primers.

Assignees

• Ye Xun
• Wu Fei
• Xu Qinghua
• Meng Xia
• Mougin Bruno
• Biomerieux Sa

Inventors

• Ye Xun
• Wu Fei
• Xu Qinghua
• Meng Xia
• Mougin Bruno

Classifications

• C12Q1/6837 Primary

  using probe arrays or probe chips (C12Q1/6874 takes precedence) · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title